A review of compounds exhibiting anti-orthopoxvirus activity in animal models.
about
Inhibition of Chikungunya Virus Replication by 1-[(2-Methylbenzimidazol-1-yl) Methyl]-2-Oxo-Indolin-3-ylidene] Amino] Thiourea(MBZM-N-IBT)Therapy and long-term prophylaxis of vaccinia virus respiratory infections in mice with an adenovirus-vectored interferon alpha (mDEF201)Identification of novel antipoxviral agents: mitoxantrone inhibits vaccinia virus replication by blocking virion assembly.A novel highly reproducible and lethal nonhuman primate model for orthopox virus infectionBiological activity of an intravenous preparation of human vaccinia immune globulin in mouse models of vaccinia virus infection.Use of the Aerosol Rabbitpox Virus Model for Evaluation of Anti-Poxvirus Agents.Activity and mechanism of action of N-methanocarbathymidine against herpesvirus and orthopoxvirus infections.Enhanced efficacy of cidofovir combined with vaccinia immune globulin in treating progressive cutaneous vaccinia virus infections in immunosuppressed hairless miceMutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype.Treatment of Vaccinia and Cowpox Virus Infections in Mice with CMX001 and ST-246.Inhibition of cowpox virus and monkeypox virus infection by mitoxantrone.Antivirals and antiviral strategies.A survey of antiviral drugs for bioweapons.Smallpox antiviral drug development: satisfying the animal efficacy rule.Crystal structure of 3-benzyl-1-[(cyclo-hexyl-idene)amino]-thio-urea.Efficacy of N-methanocarbathymidine in treating mice infected intranasally with the IHD and WR strains of vaccinia virusDifferential pathogenesis of cowpox virus intranasal infections in mice induced by low and high inoculum volumes and effects of cidofovir treatmentEctromelia Virus Disease Characterization in the BALB/c Mouse: A Surrogate Model for Assessment of Smallpox Medical CountermeasuresProgress in the discovery of compounds inhibiting orthopoxviruses in animal models.Orthopoxvirus inhibitors that are active in animal models: an update from 2008 to 2012.Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro.Animal models of orthopoxvirus infection.The design and development of drugs acting against the smallpox virus.Cidofovir Activity against Poxvirus Infections.Historical perspectives in the development of antiviral agents against poxviruses4-(3-Fluoro-phen-yl)-1-(propan-2-yl-idene)thio-semicarbazone.Comparative whole genome sequence analysis of wild-type and cidofovir-resistant monkeypoxvirus.Inhibition of Vaccinia virus entry by a broad spectrum antiviral peptide.Pharmacodynamics of cidofovir for vaccinia virus infection in an in vitro hollow-fiber infection model system.Anti-cowpox virus activities of certain adenosine analogs, arabinofuranosyl nucleosides, and 2'-fluoro-arabinofuranosyl nucleosides.Anti-influenza virus activities of 4-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)amino]-N-(4,6-dimethyl-2-pyrimidin-2-yl)benzenesulphonamide and its derivatives.Characterization and treatment of cidofovir-resistant vaccinia (WR strain) virus infections in cell culture and in mice.
P2860
Q24289284-49B90B2B-36C1-4CDA-9182-54CBED508EA9Q28743894-2D4DBE3B-F67F-490F-87BE-2ED1BF0E9358Q33302240-5EB78F02-64B8-4B14-B3B2-029195DF9D76Q33573571-7ED94F78-BE8C-4B26-8647-14BBD5503344Q33883711-968F06EC-82AF-47E2-8190-21F223E14C36Q34196187-6FE5934E-DF37-4535-A7E5-BD8DD218FDC8Q34510424-012CC89D-A0F7-4CB8-BF6E-82936E6C9947Q34922842-83C3F299-EC23-4A6C-8E81-3CB791306175Q35215440-5BA22CF0-F4C6-4906-BA6C-EF5E25C7E790Q35260533-B3705A91-69BF-42E7-9DAD-B90AD6D9BD06Q35738585-117F5DAD-0B16-4EC4-8CB2-FECA5AF561BAQ35889586-2B37D008-12EC-4D9A-8584-3CC084522CD8Q36295162-FC203CF3-2575-49FA-9367-8888EB335A50Q36441506-0958A1D3-383F-43B9-8786-93C93E1062FDQ36482045-5D1BCC66-9671-42D8-8157-DF558AD60EC9Q36499021-80A0C271-8FB5-4434-8D53-3C87B7ABE92FQ36631850-13AFE817-D61B-425B-AD03-92BD3D0DF48FQ37153772-2B400A17-B159-4F6D-96FB-9114E8E0FC19Q37331541-9267F65D-F362-4232-AA6A-F9E098637A10Q37593480-A8BEEF26-DE04-4638-8F20-243B4BB74335Q37734396-142D8F94-4C77-4DF3-9446-5EB62090ADE1Q37777545-BF658AFB-B604-4D67-BA8B-5CFFE3E2E98AQ38089868-AC855E23-D5B9-4F92-AFFE-20308C83DE98Q38614278-0466B6DA-D2CB-4449-8C42-EFB4B047C302Q38617932-2174ED2B-7DA8-4F7E-B2B1-331364A9C4C5Q40025301-101AAD1D-BA45-4A1F-91DF-224D3C601843Q41343033-2B22CC1E-A63D-4AB2-8100-4A41005F44F3Q42143723-78BCADD4-48A8-48D2-9CD0-51558D0CDC85Q42974816-1A7C032D-2E45-4165-8F96-113330EE486FQ44813635-1C8908A2-9042-4C17-A46B-9704384639A9Q45409028-1FC48BF9-C0C4-440C-8EA8-64C643AEDA0DQ45437157-89EAFD36-7B91-4663-B3FA-8BBD73E76C26
P2860
A review of compounds exhibiting anti-orthopoxvirus activity in animal models.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
A review of compounds exhibiting anti-orthopoxvirus activity in animal models.
@ast
A review of compounds exhibiting anti-orthopoxvirus activity in animal models.
@en
type
label
A review of compounds exhibiting anti-orthopoxvirus activity in animal models.
@ast
A review of compounds exhibiting anti-orthopoxvirus activity in animal models.
@en
prefLabel
A review of compounds exhibiting anti-orthopoxvirus activity in animal models.
@ast
A review of compounds exhibiting anti-orthopoxvirus activity in animal models.
@en
P1433
P1476
A review of compounds exhibiting anti-orthopoxvirus activity in animal models.
@en
P2093
Robert W Sidwell
P356
10.1016/S0166-3542(02)00199-7
P577
2003-01-01T00:00:00Z